A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.
复制标题
DOI:
10.1021/jm901808w
复制
发表时间:
2010-08-12
影响因子:
7.3
通讯作者:
Sim T
中科院分区:
文献类型:
--
作者:
Choi HG;Ren P;Adrian F;Sun F;Lee HS;Wang X;Ding Q;Zhang G;Xie Y;Zhang J;Liu Y;Tuntland T;Warmuth M;Manley PW;Mestan J;Gray NS;Sim T
The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I ‘gatekeeper’ mutation. Here we describe a Type-II T315I inhibitor GNF-7, based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold which is capable of potently inhibiting wild-type and T315I Bcr-Abl as well as other clinically relevant Bcr-Abl mutants such as G250E, E255V, F317L and M351T in biochemical and cellular assays. In addition, GNF-7 displayed significant in vivo efficacy against T315I-Bcr-Abl without appreciable toxicity in a bioluminescent xenograft mouse model using a transformed T315I-Bcr-Abl-Ba/F3 cell line that has a stable luciferase expression. GNF-7 is amongst the first type II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design next generation Bcr-Abl kinase inhibitors.
登录
查看更多内容
影响因子:
7.3
作者:
Huang, Wei-Sheng;Zhu, Xiaotian;Shakespeare, William C.
通讯作者:
Shakespeare, William C.
影响因子:
14.8
作者:
Liu, Y;Gray, NS
通讯作者:
Gray, NS
DOI:
10.1073/pnas.0504952102
发表时间:
2005-08-02
影响因子:
11.1
作者:
Carter, TA;Wodicka, LM;Lockhart, DJ
通讯作者:
Lockhart, DJ
影响因子:
--
作者:
Blencke, S;Zech, B;Daub, H
通讯作者:
Daub, H
影响因子:
11.2
作者:
Cools, J;Mentens, N;Gilliland, DG
通讯作者:
Gilliland, DG